Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis
Open Access
- 12 November 2020
- journal article
- research article
- Published by Springer Nature in npj Vaccines
- Vol. 5 (1) , 1-12
Abstract
The development of effective vaccines against bacterial lung infections requires the induction of protective, pathogen-specific immune responses without deleterious inflammation within the pulmonary environment. Here, we made use of a polysaccharide-adjuvanted vaccine approach to elicit resident pulmonary T cells to protect against aerosol Mycobacterium tuberculosis infection. Intratracheal administration of the multistage fusion protein CysVac2 and the delta-inulin adjuvant Advax™ (formulated with a TLR9 agonist) provided superior protection against aerosol M. tuberculosis infection in mice, compared to parenteral delivery. Surprisingly, removal of the TLR9 agonist did not impact vaccine protection despite a reduction in cytokine-secreting T cell subsets, particularly CD4+IFN-γ+IL-2+TNF+ multifunctional T cells. CysVac2/Advax-mediated protection was associated with the induction of lung-resident, antigen-specific memory CD4+ T cells that expressed IL-17 and RORγT, the master transcriptional regulator of Th17 differentiation. IL-17 was identified as a key mediator of vaccine efficacy, with blocking of IL-17 during M. tuberculosis challenge reducing phagocyte influx, suppressing priming of pathogen-specific CD4+ T cells in local lymph nodes and ablating vaccine-induced protection. These findings suggest that tuberculosis vaccines such as CysVac2/Advax that are capable of eliciting Th17 lung-resident memory T cells are promising candidates for progression to human trials.Keywords
Funding Information
- Department of Health | National Health and Medical Research Council
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
This publication has 46 references indexed in Scilit:
- Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challengeJournal of Controlled Release, 2018
- Development of Safe and Non-Self-Immunogenic Mucosal Adjuvant by Recombinant Fusion of Cholera Toxin A1 Subunit with Protein Transduction DomainJournal of Immunology Research, 2018
- Comparative efficacy and toxicity of two vaccine candidates against Sporothrix schenckii using either Montanide™ Pet Gel A or aluminum hydroxide adjuvants in miceVaccine, 2017
- Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptakeScience Translational Medicine, 2017
- IL-17A-mediated neutrophil recruitment limits expansion of segmented filamentous bacteriaMucosal Immunology, 2017
- Novel approaches to tuberculosis vaccine developmentInternational Journal of Infectious Diseases, 2017
- Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvantVaccine, 2016
- Advax-Adjuvanted Recombinant Protective Antigen Provides Protection against Inhalational Anthrax That Is Further Enhanced by Addition of Murabutide AdjuvantClinical and Vaccine Immunology, 2014
- Lung Neutrophils Facilitate Activation of Naive Antigen-Specific CD4+ T Cells during Mycobacterium tuberculosis InfectionThe Journal of Immunology, 2011
- ESAT-6-specific CD4 T cell responses to aerosolMycobacterium tuberculosisinfection are initiated in the mediastinal lymph nodesProceedings of the National Academy of Sciences, 2008